Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Slides:

Advertisements

Similar presentations

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Advertisements

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial David M. Fleischer, MD, A. Wesley Burks,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison Danilo Di.

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy Julie Wang, MD, Stacie M. Jones,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Hendrik Nolte, MD, PhD, David I

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial Tilo Biedermann,

House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies Moisés A. Calderón, MD, PhD, Jörg Kleine-Tebbe, MD, Allan Linneberg,

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

IL-5 T-cell responses to house dust mite are associated with the development of allergen-specific IgE responses and asthma in the first 5 years of life

Reply Journal of Allergy and Clinical Immunology

Early decreases in blood eosinophil levels with reslizumab

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy Julie Wang, MD, Stacie M. Jones,

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

Eckard Hamelmann, MD, Eric D

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

The correlation between allergic rhinitis and sleep disturbance

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Presentation transcript:

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial Pascal Demoly, MD, PhD, Waltraud Emminger, MD, Dorte Rehm, PhD, Vibeke Backer, MD, Lene Tommerup, MSc, Jörg Kleine-Tebbe, MD Journal of Allergy and Clinical Immunology Volume 137, Issue 2, Pages 444-451.e8 (February 2016) DOI: 10.1016/j.jaci.2015.06.036 Copyright © 2015 The Authors Terms and Conditions

Fig 1 Overall trial design. Subjects were treated for approximately 12 months. The subjects filled in an electronic diary during 1 week after each visit and daily during the last 8 weeks of treatment (efficacy assessment period). Journal of Allergy and Clinical Immunology 2016 137, 444-451.e8DOI: (10.1016/j.jaci.2015.06.036) Copyright © 2015 The Authors Terms and Conditions

Fig 2 Subject disposition showing number of screened, randomized, and completed subjects, as well as reasons for discontinuations. Journal of Allergy and Clinical Immunology 2016 137, 444-451.e8DOI: (10.1016/j.jaci.2015.06.036) Copyright © 2015 The Authors Terms and Conditions

Fig 3 Adjusted means of the TCRS and overall RQLQ(s) score over time for the 3 treatment groups (FAS). Error bars represent pairwise comparisons between each of the active dose and placebo groups. Asterisks designate statistically significant differences from placebo. Journal of Allergy and Clinical Immunology 2016 137, 444-451.e8DOI: (10.1016/j.jaci.2015.06.036) Copyright © 2015 The Authors Terms and Conditions

Fig 4 Individual components of the AR symptom and RQLQ(S) scores in the efficacy assessment period. Scores are shown as adjusted means. Asterisks designate statistically significant differences from placebo. Journal of Allergy and Clinical Immunology 2016 137, 444-451.e8DOI: (10.1016/j.jaci.2015.06.036) Copyright © 2015 The Authors Terms and Conditions